The post-market phase is the phase following the placement of medical devices on the market. ISO 14971 also refers to the post-production phase after development and production.
Content
This page provides a quick overview of the articles on the post-market phase:
The post-market or post-production phase comprises all activities after production until the decommissioning/decommissioning of the devices, at the latest, at the end of their service life. These activities also include use and maintenance.
Fig. 1: The post-market phase is an important part of the product life cycle.
The international regulatory requirements for the post-market phase are increasing. The EU MDR and IVDR regulations are evidence of this. In addition, there are national regulations, such as 21 CFR part 822 on post-market surveillance, and national laws and regulations on vigilance, such as the German law MPAIMV.
There are also guidelines, such as MDCG 2022-21 and MDCG 2020-6, and laws that apply to all devices, such as the Product Liability Act, which also requires post-market activities such as monitoring.
The regulations oblige manufacturers to carry out post-market surveillance, for example. To this end, manufacturers must draw up a post-market surveillance plan and collect and evaluate the post-market surveillance data in accordance with this plan. Manufacturers find it particularly difficult to analyze trends. The output then flows into reports such as the Periodic Safety Update Report (PSUR).
Depending on the class of the devices, the reports must also be published in EUDAMED.
One part of post-market surveillance is the post-market clinical follow-up (PMCF). This involves collecting clinical data to keep the clinical evaluation up to date. If the data is insufficient, PMCF studies may be necessary.
If serious incidents or trends leading to an unacceptable risk are observed in the post-market phase, manufacturers must notify the authorities (vigilance) and take corrective action.
Post-market activities include monitoring new regulations (regulatory update), monitoring vulnerabilities in off-the-shelf software, and eliminating these vulnerabilities with security patches.
These activities are not only the responsibility of manufacturers, for example, their product managers, quality management representatives, medical device consultants, and responsible persons.
Suppliers, importers, and distributors also have obligations in this post-production phase.
The essential objective of all these activities is to ensure patient safety, i.e., to minimize risks from unsafe devices.
For this reason, the third edition of the risk management standard ISO 14971 has increased the requirements for the post-production phase. The associated Technical Report ISO/TR 24971 describes these requirements in more detail.
To assess the benefit-risk ratio, manufacturers must continuously monitor and consider the state of the art.
Not doing so is one of the most common mistakes in risk management.
Do you still have questions about the post-market phase? Then, take advantage of our free micro-consulting.
If you want to delve deeper into the topic, we offer video training courses at the Medical Device University.
The post-market services take a large part of the work off your hands, from monitoring the regulations to post-market surveillance. This enables you to achieve:
Contact us if you would like support.
Conducting clinical studies in Australia is not on the radar of many medical device manufacturers. However, good reasons exist to consider this continent for clinical studies or investigations. Yet manufacturers should also be aware of Australia’s regulatory requirements and specific disadvantages. 1. Advantages and disadvantages of clinical studies in Australia 1.1 Advantages of clinical studies…
DetailsWhat MDR and IVDR confuse and why you should not talk about CAPA. The FDA (in 21 CFR part 820 – QSR) and ISO 13485 differentiate between Unfortunately, the MDR and IVDR do not clearly differentiate between these concepts. Some manufacturers also believe they can combine corrective and preventive actions into one single CAPA process. But…
DetailsClinical affairs managers play an essential role in demonstrating the safety, performance, and benefits of a medical device. They operate at the interface between science and regulation. This article sheds light on the multifaceted role of these experts: tasks and challenges, as well as earning and career opportunities. 1. Tasks of clinical affairs managers Clinical…
DetailsCompanies need to master the digital transformation quickly and successfully. This also applies to medical device manufacturers because, after all, their future depends on it. Many companies make severe mistakes during this transformation (see section 4). This article provides managers with a quick overview of the possibilities of digital transformation and gives seven tips to make it…
DetailsMedical device manufacturers are obliged to systematically collect and evaluate clinical data, both before and after the approval of their products. The EU Medical Device Regulation (MDR) has increased the requirements for the scope and quality of the required clinical data. This article provides you with an overview of the regulatory requirements and gives tips…
DetailsThis article tells you which regulatory requirements you must fulfill, how a vigilance system differs from a system for post-market surveillance, and how you can set up and operate a vigilance system quickly and in compliance with the law. 1. Definition and objectives of vigilance There are legal requirements worldwide for monitoring medical devices on…
DetailsNeither the MPG nor the MDR contain regulations on product liability, i.e., manufacturers’ liability for harm caused by defective devices. However, manufacturers should be aware that a lot of legal regulations entitle injured persons to claim compensation if a defective medical device causes harm to a patient, user, or third party. Liability may result, for example,…
DetailsPhantoms in medical technology help to develop, validate, “approve” and monitor medical devices in the markets faster and more effectively. This article describes which organizations particularly benefit from the use of these phantoms and what requirements they must meet. 1. Examples of phantoms in medical technology Anthropomorphic phantoms are replicas of bodies that behave like…
DetailsUnderstandably, laws and standards also require IT security for legacy devices. However, the way in which these requirements are formulated often leads to confusion. For example, legislators and standard committees have been unable to agree on common definitions. One definition refers to the IT security of legacy devices, another to the IT security of old…
DetailsLegislators are continually changing the regulatory framework for medical devices, as we have seen in Europe with EU Regulation 2017/745 (MDR) and EU Regulation 2017/746 (IVDR). This then raises the question of how to deal with legacy devices. These are the medical devices that manufacturers have legally placed on the market under the old directives…
Details